MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
3.620
+0.120
+3.43%
Closed 19:42 09/15 EDT
OPEN
3.600
PREV CLOSE
3.620
HIGH
3.640
LOW
3.310
VOLUME
2.08M
TURNOVER
0
52 WEEK HIGH
4.830
52 WEEK LOW
2.800
MARKET CAP
358.91M
P/E (TTM)
-2.9184
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XFOR last week (0907-0911)?
Weekly Report · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)
TipRanks · 6d ago
X4 Pharmaceuticals (XFOR) Receives a Buy from Guggenheim
TipRanks · 6d ago
X4 Pharmaceuticals Down Over 13%, On Track for Largest Percent Decrease Since June 2025 -- Data Talk
Dow Jones · 09/08 17:31
X4 Pharmaceuticals gains FDA support for 4WARD trial
TipRanks · 09/08 11:48
X4 Pharmaceuticals announces results from Type C Meeting with FDA
TipRanks · 09/08 11:25
X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial
NASDAQ · 09/08 11:22
Weekly Report: what happened at XFOR last week (0831-0904)?
Weekly Report · 09/07 09:55
More
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.